Dr. Reddy’s liposomal doxorubicin wins FDA nod

Dr. Reddy’s Laboratories (NYSE:RDY) said today that the FDA approved its doxorubicin hydrochloride liposome injection for intravenous administration.

The liposomal formulation is a therapeutic-equivalent generic version of the chemotherapeutic, Doxil.

Get the full story at our sister site, Drug Delivery Business News.

The post Dr. Reddy’s liposomal doxorubicin wins FDA nod appeared first on MassDevice.

from MassDevice http://ift.tt/2qSu4nl